ArticleCureus2024
Therapeutic Leukapheresis in a Pediatric Acute Myeloid Leukemia (AML) Crisis as a Critical Life-Saving Adjunctive Therapy: A Case Report.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hematological malignancies can present with severe complications, including hyperleukocytosis, which demands immediate intervention due to elevated leukocyte counts that increase blood viscosity and cause microcirculatory abnormalities. This case report highlights the critical role of therapeutic leukapheresis in managing a pediatric patient with acute myeloid leukemia (AML) in crisis. A six-year-old male child presented with symptoms of severe hyperleukocytosis, including high-grade fever, respiratory distress, and a significant leukocyte count (555,820/µL). Immediate interventions included intravenous hydration, antibiotics, steroids, and non-invasive ventilation, followed by therapeutic leukapheresis. The leukapheresis procedure successfully reduced the leukocyte count by 81% without any adverse events. Post-procedure treatment with etoposide further decreased the leukocyte count, leading to symptomatic improvement and stabilization of the patient. The patient was later discharged in stable condition and continued receiving induction-phase chemotherapy. This case underscores the efficacy and necessity of leukapheresis as a life-saving adjunctive therapy in pediatric AML crises, demonstrating its role in rapidly reducing leukocyte counts and preventing life-threatening complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.